What’s subsequent for the load loss drug market: tablets, rivals, insurance coverage

The urge for food for blockbuster weight reduction and diabetes medicine is much from happy. 

From recent competitors to new makes use of, the market is shortly vaulting into a brand new stage of progress. However components together with insurance coverage protection, pricing, copycat medicine and the event of recent tablets will finally decide how far the therapies will attain.

Eli Lilly and Novo Nordisk are nonetheless the dominant gamers, as demand for his or her weekly injections exhibits few indicators of slowing. Eli Lilly has pulled forward out there, saying throughout its third-quarter earnings name on Thursday that it gained share for the fifth consecutive quarter and that its medicine account for practically 6 out of 10 prescriptions throughout the injectable weight problems and diabetes class.

However each companies are centered on ramping up provide, testing new makes use of for his or her medicines and bringing the subsequent wave of weight problems medicine to sufferers, together with extra handy tablets. 

Behind them is a slate of drugmakers – from biotech upstarts to pharma giants – racing to win a slice of what some analysts count on may very well be a roughly $100 billion market by the top of the last decade. There could also be loads of room for brand spanking new entrants: McKinsey tasks that 25 million to 50 million U.S. sufferers might use GLP-1s by 2030. 

Almost each main pharmaceutical firm has guess on weight problems medicine, typically via offers with smaller builders, together with companies based mostly in China. Whereas some experimental medicine are additional alongside than others, all are doubtless years away from hitting the market, and their aggressive potential will rely upon future knowledge exhibiting their effectiveness and the way nicely sufferers tolerate them.

As competitors heats up, many sufferers are nonetheless struggling to entry the medicine. Some insurers, together with Medicare, do not cowl GLP-1s for weight problems, which might value roughly $1,000 per 30 days earlier than rebates.

Eli Lilly and Novo Nordisk have rolled out low cost applications for cash-paying sufferers to shut the hole, and extra employers are providing protection as GLP-1s show their added well being advantages like treating obstructive sleep apnea and persistent kidney illness in addition to slashing cardiovascular dangers.

Nonetheless, some sufferers proceed to make use of cheaper, copycat variations of branded therapies – regardless that these alternate options are restricted in lots of instances. Whereas Novo Nordisk and Eli Lilly’s medicine are now not in scarcity, each firms are cracking down on pharmacies, medspas and different suppliers that mass-produce and market cheaper compounded GLP-1s.

Whereas new rivals and lower-cost tablets might enable medicine to succeed in extra sufferers, entry will largely rely upon how firms like Novo Nordisk and Eli Lilly select to cost their medicine within the years forward.

Here is what to know in regards to the state of the booming weight reduction drug market. 

Eli Lilly has taken the lead within the injectable GLP-1 market. As soon as the frontrunner, Novo Nordisk misplaced floor, notably within the U.S., after provide chain points, Eli Lilly’s emergence and the unfold of compounded choices.

Eli Lilly eclipsed its Danish rival for the primary time in Might, when it secured 53% of the market in the course of the first quarter. In August, Eli Lilly mentioned its share rose to 57% in the course of the second quarter.  

TD Cowen analyst Michael Nedelcovych mentioned that is largely as a result of Eli Lilly’s injections are superior to Novo Nordisk’s medicine by way of security and efficacy. Eli Lilly’s diabetes drug Mounjaro is seen as a greater remedy than Novo Nordisk’s Ozempic, he famous. Actual-world knowledge and a head-to-head scientific trial have proven that Eli Lilly’s weight problems injection Zepbound results in extra weight reduction than Novo Nordisk’s Wegovy.

“It is higher efficacy, and not less than anecdotally in real-world practices, it is higher tolerability,” Nedelcovych mentioned. “In our enterprise, that is often all that is required for share positive factors, and I feel we’re seeing that play out in a short time.” 

Buyers have unloaded Novo Nordisk’s inventory, which has fallen virtually 40% this 12 months. Novo Nordisk reduce its revenue and gross sales forecast in July, saying compounded medicine had reduce into Wegovy’s market. The corporate had already lowered its 2025 outlook in Might.

As competitors mounts, knowledge on Novo Nordisk’s experimental medicines additionally underwhelmed Wall Road and raised considerations in regards to the progress of its drug portfolio past Wegovy and Ozempic. 

In a word in September, BMO Capital Markets analyst Evan Seigerman mentioned the corporate raised expectations too excessive for its next-generation weight problems drug CagriSema, was sluggish to launch direct-to-consumer gross sales of its well-liked medicine and had a “tepid preliminary response” to compounders promoting copycat therapies. 

What’s extra, Medicare is negotiating the worth of Novo Nordisk’s semaglutide – the energetic ingredient in Ozempic, Wegovy and the corporate’s diabetes tablet Rybelsus – efficient in 2027, which might additional reduce into income. Eli Lilly’s tirzepatide, the energetic ingredient in Mounjaro and Zepbound, doubtless will not be topic to cost discussions till the top of the last decade. 

Novo Nordisk is betting its new CEO, Mike Doustdar, will assist it regain its footing. He took the helm in late July after the board ousted former prime govt Lars Fruergaard Jorgensen. 

Doustdar is not losing any time to make adjustments: Novo Nordisk in September introduced plans to chop round 9,000 roles, or roughly 11.5% of its international workforce.

There may be nonetheless turbulence on the pharmaceutical big. On Tuesday, Novo Nordisk mentioned a number of board members will step down after clashing with the controlling shareholder, the Novo Nordisk Basis, on the make-up of the board.

Novo Nordisk nonetheless faces one other main problem: the persistence of cheaper, compounded variations of semaglutide. 

The corporate for now “is certainly way more susceptible” to competitors from copycats than Eli Lilly is, largely as a result of most of them comprise or declare to be semaglutide, mentioned Cowen’s Nedelcovych. He added that Novo Nordisk is “already on its again foot” out there, so it may’t afford to lose extra share.

Sufferers flocked to compounded GLP-1s when branded injections had been briefly provide during the last two years, or not coated by their insurance coverage.

Compounding is a apply the place pharmacies combine components of a drug to create a specialised model tailor-made to a affected person’s particular wants, similar to these with allergic reactions to sure components. When a branded drug is briefly provide, pharmacies are allowed to make bigger portions of compounded variations to assist fill the hole.

However Novo Nordisk and Eli Lilly have each invested billions to extend manufacturing capability for his or her injections, which has already began to repay. 

The FDA declared an finish to the shortages of tirzepatide and semaglutide during the last 12 months. These choices legally barred compounding pharmacies from making and promoting copycats of these medicine by deadlines that handed earlier this 12 months, besides in uncommon instances the place it is medically crucial. 

Novo Nordisk in June mentioned some mass, so-called 503B compounding pharmacies have scaled again manufacturing, however accused others — together with these tied to Hims & Hers — of constant to promote the medicine below the “false guise” of personalization. In August, Novo Nordisk executives famous that round 1 million U.S. sufferers are taking compounded GLP-1s.

The problem additionally plagues Eli Lilly. Whereas the FDA regulates 503B pharmacies, most 503A websites fall below state oversight. Nedelcovych likened shutting them right down to “a case of whack-a-mole.” Eli Lilly and Novo Nordisk’s lawsuits in opposition to telehealth firms, pharmacies and others since 2023 have consumed time and sources, with combined authorized outcomes.

The FDA additionally does not seem like taking an aggressive stance on compounded GLP-1s: The company in September revealed a “inexperienced listing” of imported GLP-1 drug components deemed secure to let into the nation. 

Restricted insurance coverage protection for GLP-1s is obstructing out sufferers who cannot afford their roughly $1,000 month-to-month worth tags. That entry hole has turn into a political and company flashpoint, with stress mounting on employers and the federal government to increase protection.

Many well being plans, together with Medicare, cowl GLP-1s for the remedy of diabetes however not weight problems. Medicaid protection of weight problems medicine is sparse and varies by state, in keeping with well being coverage analysis group KFF. 

Protection for GLP-1s for weight problems has ticked up barely: A Might survey of greater than 300 firms by the Worldwide Basis of Worker Profit Plans, or IFEBP, discovered that 36% offered protection for GLP-1s for each weight reduction and diabetes, up from 34% in 2024. 

Nonetheless, many employers and well being plans stay hesitant as a consequence of excessive prices. In 2025, weight-loss GLP-1s accounted for a median of 10.5% of whole annual claims amongst employers, up from 8.9% in 2024 and 6.9% in 2023, IFEBP discovered.

“If employers weren’t already on board earlier than, they’re nonetheless ready,” mentioned Julie Stich, vp of content material at IFEBP. “The associated fee challenge continues to be a serious, main challenge for them.”

Some plans are involved that sufferers will not keep on the medicine long run as a consequence of gastrointestinal unwanted effects, similar to nausea and vomiting, and will regain the load they misplaced, mentioned John Crable, senior vp of Company Synergies, a nationwide insurance coverage and worker advantages brokerage and consultancy. Employers, which might expertise excessive turnover, are additionally hesitant to cowl pricey medicine for employees who might depart the corporate inside a couple of years, Crable added.

Crable added that new direct-to-consumer applications from Eli Lilly and Novo Nordisk — which let sufferers pay money for therapies at lower than half their month-to-month listing worth — may discourage employer protection.

Sew mentioned employers even have questions on how oral weight problems medicine, which may very well be accessible as quickly as 2025, might have an effect on demand and prices.

However she mentioned protection might nonetheless develop, particularly as GLP-1s acquire new approvals for extra persistent situations. Wegovy is cleared for decreasing cardiovascular threat and fatty liver illness, whereas Zepbound is accredited for sleep apnea.

Novo Nordisk can also be testing semaglutide in Alzheimer’s, with preliminary late-stage trial outcomes anticipated this 12 months. If that examine exhibits that GLP-1s scale back the danger of cognitive decline, “it will give a giant increase” to Novo Nordisk and Eli Lilly as a result of it might encourage sufferers to remain on them longer, mentioned Leerink Companions analyst David Risinger.

“You are paying for the GLP-1 drug with the hope that weight problems or these different situations will enhance, in order that health-care prices for these particular person workers will get higher as you progress ahead,” Stich mentioned.

Some plans have additionally launched value controls, like BMI thresholds, to handle spending.

Stich added that broader Medicare protection might finally drive non-public insurers to observe swimsuit. The Trump administration plans to pilot protection of weight reduction medicine below Medicare and Medicaid, which might increase entry to tens of millions of older People, the Washington Put up reported in August.

Whereas Novo Nordisk already sells an oral GLP-1 for diabetes, the corporate and Eli Lilly might quickly deliver tablets particularly for weight reduction to sufferers.

Some consultants and analysts imagine they may essentially shift the market, serving to extra sufferers entry remedy and assuaging the availability shortfalls of present injections. However others elevate questions on how a lot of a task tablets will play within the area provided that some seem like much less efficient than injections and produce larger unwanted effects.

Novo Nordisk’s 25-milligram oral semaglutide might win approval for weight problems by the top of the 12 months, which might make it the primary needle-free various for weight reduction available on the market. The each day tablet seems to be barely simpler than a competing oral GLP-1 from Eli Lilly known as orforglipron, based mostly on knowledge from separate section three trials. 

Nonetheless, Eli Lilly’s tablet might have a couple of notable benefits. Each medicine work by mimicking the GLP-1 intestine hormone to suppress urge for food and regulate blood sugar. However whereas Novo Nordisk’s tablet is a peptide medicine, orforglipron is a small-molecule drug.

Which means Eli Lilly’s remedy is absorbed extra simply within the physique and does not require dietary restrictions like Novo Nordisk’s does. Some analysts say orforglipron will even be simpler to fabricate at scale than Novo Nordisk’s, which is essential as demand for weight problems and diabetes injections outpaces provide. In August, Eli Lilly CEO David Ricks instructed CNBC the firm hopes to launch its tablet globally “this time subsequent 12 months.” 

In an August word, Goldman Sachs analysts forecast each day oral tablets will seize 24% share — or round $22 billion — of the 2030 international weight reduction drug market, which they count on to be price $95 billion. 

The Goldman analysts mentioned they count on Eli Lilly’s tablet to have a 60% share — or roughly $13.6 billion — of the marketplace for each day oral therapies in 2030. They count on Novo Nordisk’s oral semaglutide to have a 21% share — or round $4 billion — of that phase. The remaining 19% slice will go to different rising tablets, the analysts mentioned.

TD Cowen’s Nedelcovych mentioned he has been “treading sort of cautiously” in his outlook for oral weight reduction medicine. He mentioned that is partially as a result of doctor consultants and different consultants imagine injections, that are simpler and simpler to tolerate than tablets, will dominate the marketplace for the foreseeable future. 

Nedelcovych mentioned the comfort of a once-daily tablet is probably not sufficient to persuade sufferers to change, since a few of them “actually do not thoughts” taking an injection as soon as every week. Nedelcovych added that really fizzling out injections and switching to tablets as a upkeep routine “additionally does not appear to make a ton of sense, once we ask physicians about it.” 

He mentioned if tablets are much less efficient at selling weight reduction, it raises considerations that sufferers who initially lose important weight on an injection might acquire some again after switching to an oral drug.  A section three examine from Eli Lilly, which is learning orforglipron’s means to keep up weight reduction, will deliver extra readability on that challenge. 

Corporations have mentioned that tablets might attain sufferers who do not take injections as a result of they’re afraid of needles. However Nedelcovych mentioned the “destiny of oral weight reduction therapies might actually revolve” round one other class of individuals: sufferers who may gain advantage from weight reduction therapies however do not take injections as a result of they imagine they’re meant for these with severe illnesses.

“They’re actually simply invisible to {the marketplace} proper now,” he mentioned. “However they may have totally different views about an oral remedy, which may very well be thought of extra like a vitamin so they might be extra amenable to taking that.” 

The query prime of thoughts for well being consultants is how firms will worth the tablets. 

“If it wasn’t for the truth that they are often made extra cheaply, I would not care” about tablets, mentioned Dr. Caroline Apovian, co-director of the Heart for Weight Administration and Wellness at Brigham and Girls’s Hospital.

The direct-to-consumer platforms from Eli Lilly and Novo Nordisk supply Zepbound and Wegovy for roughly $500 a month. She mentioned much less efficient tablets with extra unwanted effects should be priced decrease than that if firms need health-care suppliers to prescribe them first over injections. 

It is nonetheless unclear who would be the subsequent viable participant to enter the load loss drug area. Many experimental medicine from different firms might not attain sufferers till the top of the last decade. 

Nonetheless, some drugmakers have made strides during the last 12 months and a half, inking offers with weight problems biotechs or releasing promising knowledge on experimental therapies. A number of firms try to drive innovation with new medicine that promote weight reduction in a different way, are taken much less continuously or protect muscle mass, amongst different adjustments. 

Some traders are wanting to see a drug that promotes much more weight reduction than Wegovy and Zepbound, which has hit these firms’ shares when their therapies do not meet lofty expectations in scientific trials. However some well being consultants say many sufferers need not lose greater than 20% of their weight. 

“I’m not even on the lookout for larger weight reduction anymore. What’s flawed with 16% and 22% weight reduction? Nothing, proper?” mentioned Apovian, referring to the degrees of weight reduction seen with some present and experimental medicine. 

Apovian mentioned she is on the lookout for therapies that focus on new intestine hormones, which might deal with sufferers who might not drop extra pounds on GLP-1s. She pointed to medicine focusing on amylin analogs – an rising type of weight reduction remedy that mimics a hormone co-secreted with insulin within the pancreas to suppress urge for food and scale back meals consumption.

A number of drugmakers, together with Novo Nordisk and Eli Lilly, are betting on amylin analogs as a part of the subsequent wave of weight problems therapies

Different consultants have mentioned that a super competitor would promote weight reduction whereas being simpler to tolerate than present injections. That is as a result of many individuals discontinue these injections – and will not expertise the complete well being advantages – as a consequence of gastrointestinal unwanted effects similar to nausea and vomiting. 

With out late-stage trial knowledge on any of the brand new rivals, it is too early to say who will have the ability to deal with that challenge.

Some medicine are a lot nearer to answering that query than others. 

For instance, Amgen in March mentioned it has began two essential late-stage trials for its experimental weight reduction injection MariTide, which is designed to be taken month-to-month and even much less continuously and promotes weight reduction in a different way from rivals. 

In a mid-stage examine, sufferers with weight problems taking MariTide misplaced as much as 16.2% of their weight in a single 12 months when analyzing all contributors no matter discontinuations, or as much as 19.9% when solely analyzing those that stayed on the remedy. However sufferers skilled a excessive fee of unwanted effects and discontinuations within the trial. 

These outcomes help the corporate’s choice to make use of a slower dosing schedule over eight weeks to make the drug extra tolerable in section three research. 

Some pharmaceutical firms have turned to China for his or her weight problems bets. For instance, Merck in December snagged the rights to an early-stage experimental GLP-1 tablet from Chinese language drugmaker Hansoh Pharma, in a deal price as much as $2 billion. 

That acquisition and different smaller gamers raised questions in regards to the destiny of public U.S.-based weight problems biotechs similar to Viking Therapeutics, which had been as soon as seen as sizzling takeover targets. Some analysts argue that their experimental medicine, most of that are nonetheless in mid-stage improvement, haven’t differentiated themselves sufficient from present therapies. 

“Until and till these molecules present that they honestly are differentiated in section three, I do not assume there’s actually a cause for given pharma to put out a big transaction to realize entry to it,” mentioned TD Cowen’s Nedelcovych. 

He mentioned the “clearest path ahead” for U.S.-based weight problems biotechs is probably going inking partnerships with bigger companies to develop and commercialize their medicine.

However Nedelcovych famous that “there actually aren’t too many massive pharmas who aren’t already spoken for at this level.”